Treatment modalities
| . | Treated patients (N = 37) . |
|---|---|
| Chemotherapy adapted to the clone, n (%) | 29 (78%) |
| Median time to treatment, mo | 3 (1-20) |
| Alkylating agent-dexamethasone* | 5 (17%) |
| Bortezomib based regimen-dexamethasone† | 22 (76%) |
| Prednisone-rituximab‡ | 2 (7%) |
| Immunosuppressive therapy, n | 8 (22%) |
| Median time to treatment, mo | 4 (1-54) |
| Prednisone-dexamethasone | 4 (50%) |
| Prednisone-cyclophosphamide | 1 (12.5%) |
| Prednisone-rituximab | 1 (12.5%) |
| Prednisone-mycophenolate mofetil | 1 (12.5%) |
| Prednisone-azathioprine | 1 (12.5%) |
| . | Treated patients (N = 37) . |
|---|---|
| Chemotherapy adapted to the clone, n (%) | 29 (78%) |
| Median time to treatment, mo | 3 (1-20) |
| Alkylating agent-dexamethasone* | 5 (17%) |
| Bortezomib based regimen-dexamethasone† | 22 (76%) |
| Prednisone-rituximab‡ | 2 (7%) |
| Immunosuppressive therapy, n | 8 (22%) |
| Median time to treatment, mo | 4 (1-54) |
| Prednisone-dexamethasone | 4 (50%) |
| Prednisone-cyclophosphamide | 1 (12.5%) |
| Prednisone-rituximab | 1 (12.5%) |
| Prednisone-mycophenolate mofetil | 1 (12.5%) |
| Prednisone-azathioprine | 1 (12.5%) |